Missing content? – Request curation!
Request curation for specific Genes, variants, or PubMed publications.
Have questions, comments or suggestions? - Let us know!
Email us at : ckbsupport@jax.org
Therapy Name | Nazartinib |
Synonyms | |
Therapy Description |
Nazartinib (EGF816) is a third generation EGFR inhibitor with selectivity towards mutant forms of EGFR, resulting in inhibition of tumor cell growth (PMID: 27433829). |
Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
---|---|---|---|---|
Nazartinib | EGF816|EGF-816 | EGFR Inhibitor 3rd gen 20 | Nazartinib (EGF816) is a third generation EGFR inhibitor with selectivity towards mutant forms of EGFR, resulting in inhibition of tumor cell growth (PMID: 27433829, PMID: 31954624). |
Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
---|---|---|---|---|---|---|---|
ERBB2 G778_P780dup | Advanced Solid Tumor | resistant | Nazartinib | Preclinical - Cell culture | Actionable | In a preclinical study, transformed cells expressing ERBB2 (HER2) G778_P780dup were resistant to Nazartinib (EGF816) in culture (PMID: 31588020). | 31588020 |
ERBB2 D769Y | Advanced Solid Tumor | sensitive | Nazartinib | Preclinical - Cell culture | Actionable | In a preclinical study, Nazartinib (EGF816) inhibited survival of transformed cells expressing ERBB2 (HER2) D769Y in culture (PMID: 31588020). | 31588020 |
ERBB2 D769H | Advanced Solid Tumor | sensitive | Nazartinib | Preclinical - Cell culture | Actionable | In a preclinical study, Nazartinib (EGF816) inhibited survival of transformed cells expressing ERBB2 (HER2) D769H in culture (PMID: 31588020). | 31588020 |
ERBB2 V842I | Advanced Solid Tumor | resistant | Nazartinib | Preclinical - Cell culture | Actionable | In a preclinical study, transformed cells expressing ERBB2 (HER2) V842I were resistant to Nazartinib (EGF816) in culture (PMID: 31588020). | 31588020 |
ERBB2 G776delinsVC | Advanced Solid Tumor | resistant | Nazartinib | Preclinical - Cell culture | Actionable | In a preclinical study, transformed cells expressing ERBB2 (HER2) G776delinsVC were resistant to Nazartinib (EGF816) in culture (PMID: 31588020). | 31588020 |
ERBB2 V773M | Advanced Solid Tumor | resistant | Nazartinib | Preclinical - Cell culture | Actionable | In a preclinical study, transformed cells expressing ERBB2 (HER2) V773M were resistant to Nazartinib (EGF816) in culture (PMID: 31588020). | 31588020 |
ERBB2 G776delinsLC | Advanced Solid Tumor | resistant | Nazartinib | Preclinical - Cell culture | Actionable | In a preclinical study, transformed cells expressing ERBB2 (HER2) G776delinsLC were resistant to Nazartinib (EGF816) in culture (PMID: 31588020). | 31588020 |
ERBB2 L869R | Advanced Solid Tumor | sensitive | Nazartinib | Preclinical - Cell culture | Actionable | In a preclinical study, Nazartinib (EGF816) inhibited survival of transformed cells expressing ERBB2 (HER2) L869R in culture (PMID: 31588020). | 31588020 |
ERBB2 V777L | Advanced Solid Tumor | sensitive | Nazartinib | Preclinical - Cell culture | Actionable | In a preclinical study, Nazartinib (EGF816) inhibited survival of transformed cells expressing ERBB2 (HER2) V777L in culture (PMID: 31588020). | 31588020 |
ERBB2 L755P | Advanced Solid Tumor | resistant | Nazartinib | Preclinical - Cell culture | Actionable | In a preclinical study, transformed cells expressing ERBB2 (HER2) L755P were resistant to Nazartinib (EGF816) in culture (PMID: 31588020). | 31588020 |
ERBB2 L786V | Advanced Solid Tumor | sensitive | Nazartinib | Preclinical - Cell culture | Actionable | In a preclinical study, Nazartinib (EGF816) inhibited survival of transformed cells expressing ERBB2 (HER2) L786V in culture (PMID: 31588020). | 31588020 |
ERBB2 G778_S779insLPS | Advanced Solid Tumor | resistant | Nazartinib | Preclinical - Cell culture | Actionable | In a preclinical study, transformed cells expressing ERBB2 (HER2) G778_S779insLPS were resistant to Nazartinib (EGF816) in culture (PMID: 31588020). | 31588020 |
ERBB2 Y772_A775dup | Advanced Solid Tumor | resistant | Nazartinib | Preclinical - Cell culture | Actionable | In a preclinical study, transformed cells expressing ERBB2 (HER2) Y772_A775dup were resistant to Nazartinib (EGF816) in culture (PMID: 31588020). | 31588020 |
ERBB2 G776delinsVV | Advanced Solid Tumor | sensitive | Nazartinib | Preclinical - Cell culture | Actionable | In a preclinical study, transformed cells expressing ERBB2 (HER2) G776delinsVV were resistant to Nazartinib (EGF816) in culture (PMID: 31588020). | 31588020 |
ERBB2 D769N | Advanced Solid Tumor | sensitive | Nazartinib | Preclinical - Cell culture | Actionable | In a preclinical study, Nazartinib (EGF816) inhibited survival of transformed cells expressing ERBB2 (HER2) D769N in culture (PMID: 31588020). | 31588020 |
ERBB2 L755S | Advanced Solid Tumor | sensitive | Nazartinib | Preclinical - Cell culture | Actionable | In a preclinical study, Nazartinib (EGF816) inhibited survival of transformed cells expressing ERBB2 (HER2) L755S in culture (PMID: 31588020). | 31588020 |
Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
---|---|---|---|---|---|---|
NCT02108964 | Phase Ib/II | Nazartinib | A Phase I/II, Multicenter, Open-label Study of EGFRmut-TKI EGF816, Administered Orally in Adult Patients With EGFRmut Solid Malignancies | Active, not recruiting | USA | CAN | 7 |